Santos João Victor de Oliveira, Porto Ana Lúcia Figueiredo, Cavalcanti Isabella Macário Ferro
Laboratory of Immunopathology Keizo Asami (LIKA), Federal University of Pernambuco (UFPE), Recife 50670-901, Pernambuco, Brazil.
Department of Morphology and Animal Physiology Animal, Federal Rural University of Pernambuco (UFRPE), Recife 52171-900, Pernambuco, Brazil.
Antibiotics (Basel). 2021 May 2;10(5):520. doi: 10.3390/antibiotics10050520.
Antibiotic monotherapy may become obsolete mainly due to the continuous emergence of resistance to available antimicrobials, which represents a major uncertainty to human health. Taking into account that natural products have been an inexhaustible source of new compounds with clinical application, lectins are certainly one of the most versatile groups of proteins used in biological processes, emerging as a promising alternative for therapy. The ability of lectins to recognize carbohydrates present on the cell surface allowed for the discovery of a wide range of activities. Currently the number of antimicrobials in research and development does not match the rate at which resistance mechanisms emerge to an effective antibiotic monotherapy. A promising therapeutic alternative is the combined therapy of antibiotics with lectins to enhance its spectrum of action, minimize adverse effects, and reduce resistance to treatments. Thus, this review provides an update on the experimental application of antibiotic therapies based on the synergic combination with lectins to treat infections specifically caused by multidrug-resistant and biofilm-producing , , and . We also briefly discuss current strategies involving the modulation of the gut microbiota, its implications for antimicrobial resistance, and highlight the potential of lectins to modulate the host immune response against oxidative stress.
抗生素单一疗法可能会过时,主要原因是对现有抗菌药物的耐药性不断出现,这对人类健康构成了重大不确定性。考虑到天然产物一直是具有临床应用价值的新化合物的不竭来源,凝集素无疑是生物过程中使用的最具多功能性的蛋白质组之一,成为一种有前景的治疗替代方案。凝集素识别细胞表面存在的碳水化合物的能力使得人们发现了广泛的活性。目前,研发中的抗菌药物数量与有效抗生素单一疗法的耐药机制出现速度不匹配。一种有前景的治疗替代方案是抗生素与凝集素联合治疗,以扩大其作用谱,将不良反应降至最低,并降低对治疗的耐药性。因此,本综述提供了基于与凝集素协同组合的抗生素疗法的实验应用最新情况,以治疗由多重耐药和产生生物膜的[具体病原体]引起的感染。我们还简要讨论了当前涉及调节肠道微生物群的策略、其对抗菌药物耐药性的影响,并强调了凝集素调节宿主抗氧化应激免疫反应的潜力。